Sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists, and the risk of macrovascular, and microvascular complications among patients with type 2 diabetes and non-alcoholic fatty liver disease

被引：0
|
作者：
Bea, Sungho [1 ]
Filion, Kristian B. [2 ]
Shin, Ju-Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
58
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [21] Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials
    Rizzi, Alessandro
    Kloecker, David E.
    Pitocco, Dario
    Khunti, Kamlesh
    Davies, Melanie J.
    Zaccardi, Francesco
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (02)
  • [22] Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus
    Dhatariya, Ketan
    Levy, Nicholas
    Russon, Kim
    Patel, Anil
    Frank, Claire
    Mustafa, Omar
    Newland-Jones, Philip
    Rayman, Gerry
    Tinsley, Sarah
    Dhesi, Jugdeep
    BRITISH JOURNAL OF ANAESTHESIA, 2024, 132 (04) : 639 - 643
  • [23] Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
    Ding, Chen
    Tang, Yaxin
    Zhu, Wenqiang
    Huang, Piaopiao
    Lian, Pingan
    Ran, Juanli
    Huang, Xiansheng
    ACTA DIABETOLOGICA, 2022, 59 (04) : 519 - 533
  • [24] The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon Like Peptide -1 Receptor Agonists
    Jung, Chan-Hee
    Mok, Ji-Oh
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2019, 28 (01) : 18 - 29
  • [25] Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
    Chen Ding
    Yaxin Tang
    Wenqiang Zhu
    Piaopiao Huang
    Pingan Lian
    Juanli Ran
    Xiansheng Huang
    Acta Diabetologica, 2022, 59 : 519 - 533
  • [26] Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications
    Pineda, Elmor D.
    Liao, I-Chia
    Godley, Paul J.
    Michel, Jeffrey B.
    Rascati, Karen L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (05): : 610 - +
  • [27] Cardiovascular outcomes with Glucagon-like Peptide-1 receptor agonists and Sodium-glucose Cotransporter-2 Inhibitors in patients with ischemic stroke in the community
    Sheffeh, Mohammad Ali
    Magana, Andres Estrada
    Medina-Inojosa, Jose
    Aviles, Laura Ortega
    Bianchettin, Rosana
    Medina-Inojosa, Betsy
    Klaas, James
    Brown, Robert
    Lopez-Jimenez, Francisco
    CIRCULATION, 2024, 150
  • [28] Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease
    Rhee, Jinnie J.
    Han, Jialin
    Montez-Rath, Maria E.
    Chertow, Glenn M.
    DIABETES OBESITY & METABOLISM, 2024, 26 (04): : 1273 - 1281
  • [29] Effects of glucagon-like peptide-1 agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Dong, Yajie
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 4 - 4
  • [30] Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
    Ni, David
    Kokkinos, Peter
    Nylen, Eric S.
    MILITARY MEDICINE, 2024, 189 (11-12) : 2369 - 2373
12345